In 2013, the US Food and Drug Administration made an unprecedented recommendation, advising that women should receive a lower dosage of the insomnia drug zolpidem than men. The rationale behind it was that medication seemed to affect women for longer periods, which could become a safety issue.
However, in 2019, research conducted at Tufts University concluded that the differential effect of the medication had nothing to do with sex. Rather, researchers found that what determined the rate at which the person cleared the drug from their system was their body size. The report concluded that the reduced prescribed dosage for women could in fact lead to underdosing and a failure
→ Continue reading at Wired - Science